<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APAF1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APAF1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APAF1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=APAF1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a>, <a href="/wiki/neurodegenerative_diseases" style="color:#ef9a9a">neurodegenerative_diseases</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">30 edges</a></td>
</tr>
</table>
APAF1 (Apoptotic Protease-Activating Factor 1) is a critical regulator of the intrinsic (mitochondrial) [apoptosis](/mechanisms/apoptosis) pathway. It serves as a molecular scaffold for the formation of the apoptosome complex, which orchestrates caspase-9 activation in response to mitochondrial cytochrome c release. [@apaf2001] APAF1 plays a fundamental role in neuronal survival and death decisions, making it a key player in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multiple system atrophy. [@apaf2006][@apaf2014]
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">APAF1 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APAF1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>APAF1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=APAF1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a>, <a href="/wiki/neurodegenerative_diseases" style="color:#ef9a9a">neurodegenerative_diseases</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">30 edges</a></td>
</tr>
</table>
APAF1 (Apoptotic Protease-Activating Factor 1) is a critical regulator of the intrinsic (mitochondrial) [apoptosis](/mechanisms/apoptosis) pathway. It serves as a molecular scaffold for the formation of the apoptosome complex, which orchestrates caspase-9 activation in response to mitochondrial cytochrome c release. [@apaf2001] APAF1 plays a fundamental role in neuronal survival and death decisions, making it a key player in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and multiple system atrophy. [@apaf2006][@apaf2014]
APAF1 is a 130 kDa cytosolic protein that functions as the central hub of the intrinsic apoptosis pathway. Upon mitochondrial outer membrane permeabilization (MOMP), cytochrome c is released into the cytosol where it binds to APAF1's WD40 repeat domain. This binding induces a conformational change that allows APAF1 to oligomerize into a heptameric complex known as the apoptosome. [@apoptosome2005] The apoptosome then recruits and activates procaspase-9 through a CARD-CARD interaction, initiating the caspase cascade that executes programmed cell death. [@apaf2000]
In neurons, the regulation of APAF1-mediated apoptosis is particularly critical due to the post-mitotic nature of these cells. Excessive neuronal apoptosis during development can lead to microcephaly, while insufficient apoptosis may result in abnormal brain development. [@apaf2002] In the adult brain, dysregulation of APAF1 function contributes to neuronal loss in various neurodegenerative conditions.
APAF1 contains several distinct structural domains that mediate its functions:
N-terminal CARD Domain (Caspase Recruitment Domain): The CARD domain (residues 1-97) mediates specific interaction with the CARD domain of procaspase-9. This domain is essential for apoptosome formation and caspase-9 recruitment. [@apaf2001]
Central Linker Region: The linker region connects the CARD domain to the WD40 domain and undergoes conformational changes upon cytochrome c binding. This conformational switch is critical for APAF1 oligomerization. [@apoptosome2005]
WD40 Repeat Domain: The C-terminal WD40 repeat domain (residues 315-424) consists of multiple Trp-Asp (WD) repeats that form a beta-propeller structure. This domain serves as the primary cytochrome c binding site and regulates APAF1's apoptotic activity in a phosphorylation-dependent manner. [@apaf2001]
The activation of APAF1 and apoptosome formation follows a carefully regulated sequence:
APAF1 plays a complex role in Alzheimer's disease pathogenesis. Amyloid-beta (Aβ) peptide accumulation triggers mitochondrial dysfunction and cytochrome c release, leading to APAF1 activation and subsequent caspase-9-mediated neuronal apoptosis. [@apaf2006] Studies show increased APAF1 expression in AD brain tissue, particularly in vulnerable regions like the hippocampus and entorhinal cortex. [@apaf2004] The apoptosome pathway contributes to the progressive neuronal loss characteristic of AD.
In Parkinson's disease, APAF1 is implicated in dopaminergic neuron loss. Mitochondrial dysfunction caused by [alpha-synuclein](/proteins/alpha-synuclein) aggregation, PINK1/Parkin pathway defects, and environmental toxins can trigger APAF1-mediated apoptosis. [@apaf2014] Immunohistochemical studies have demonstrated increased apoptosome-related proteins, including APAF1 and caspase-9, in Lewy bodies in PD and dementia with Lewy bodies brains. [@apaf2014b]
APAF1 and activated caspase-9 have been detected in glial and neuronal cytoplasmic inclusions in multiple system atrophy (MSA), suggesting that the apoptosome pathway contributes to neurodegeneration in this atypical parkinsonian disorder. [@apaf2016]
Following cerebral ischemia, mitochondrial dysfunction leads to cytochrome c release and APAF1 activation in neurons. The apoptosome pathway is a key mediator of ischemic neuronal death, making APAF1 a potential therapeutic target for stroke treatment. [@apaf2011]
APAF1 activity is regulated at multiple levels:
Phosphorylation: APAF1 can be phosphorylated by various kinases, which modulates its ability to form the apoptosome. Phosphorylation at specific residues can inhibit or promote APAF1 activation.
Bcl-2 Family Proteins: The balance between anti-apoptotic (Bcl-2, Bcl-xL, MCL1) and pro-apoptotic (Bax, Bak) Bcl-2 family proteins determines whether cytochrome c is released and APAF1 is activated. [@apaf2015]
Inhibitor of Apoptosis Proteins (IAPs): XIAP and other IAPs can directly inhibit caspase-9 and downstream executioner caspases, providing an additional layer of regulation. [@apaf2004]
Transcriptional Regulation: APAF1 expression is regulated at the transcriptional level by various transcription factors, including p53, which can upregulate APAF1 in response to DNA damage.
Targeting the APAF1-apoptosome pathway offers potential therapeutic strategies for neurodegenerative diseases:
Caspase-9 Inhibitors: Selective caspase-9 inhibitors could protect neurons from excessive apoptosis while preserving the essential functions of the apoptosis pathway in other tissues.
Cytochrome c Release Blockers: Agents that prevent mitochondrial cytochrome c release indirectly inhibit APAF1 activation.
Apoptosome Modulators: Small molecules that modulate apoptosome formation or stability are being investigated for neuroprotective effects.
The following diagram shows the key molecular relationships involving APAF1 Gene discovered through SciDEX knowledge graph analysis: